NCT00253422 Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors Status COMPLETED Phase PHASE3
NCT00244998 Fulvestrant in Treating Patients With Advanced Prostate Cancer Status COMPLETED Phase PHASE2
NCT00241449 A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer Status COMPLETED Phase PHASE3
NCT00217464 Fulvestrant in Treating Patients With Recurrent Prostate Cancer Status TERMINATED Phase PHASE2
NCT00201864 Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer Status COMPLETED Phase PHASE2
NCT00183963 A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) Status TERMINATED Phase PHASE2
NCT00146601 Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Status COMPLETED Phase PHASE2
NCT00126464 Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast Status UNKNOWN Phase NA
NCT00100854 Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT00099437 Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT00093002 Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer Status COMPLETED Phase PHASE2
NCT00082810 Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer Status COMPLETED Phase PHASE2
NCT00075764 S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer Status COMPLETED Phase PHASE3
NCT00065325 The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer Status COMPLETED Phase PHASE3
NCT00057941 Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Status COMPLETED Phase PHASE2
NCT00010153 ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer Status TERMINATED Phase PHASE3
NCT00006903 Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Status UNKNOWN Phase PHASE2